Disease | polycystic ovary syndrome |
Symptom | C0206081|hyperandrogenism |
Sentences | 30 |
PubMedID- 20663984 | polycystic ovary syndrome (pcos) is associated with hyperandrogenism and insulin resistance, possibly reflecting defects in skeletal muscle and adipocyte insulin signaling. |
PubMedID- 21228310 | Small trials also suggest that metformin has a positive impact on insulin resistance and hyperandrogenism in patients with polycystic ovary syndrome (36,37) or precocious pubarche (38,39). |
PubMedID- 26476820 | Due to the characteristics of hyperandrogenism in polycystic ovary syndrome (pcos), it is plausible that women with pcos may have increased pelvic floor muscle (pfm) thickness and neuromuscular activity levels compared with controls. |
PubMedID- 23575700 | Introduction and hypothesis: hyperandrogenism in women with polycystic ovary syndrome (pcos) could increase muscle mass and thereby pelvic floor muscle (pfm) strength, reducing the risk of urinary incontinence (ui). |
PubMedID- 26034121 | Hirsutism induced by hyperandrogenism can be associated with polycystic ovary syndrome, 21-hydroxylase (oh) deficiency or androgen-secreting tumors, including ovarian and adrenal tumors. |
PubMedID- 23194004 | Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. |
PubMedID- 21177795 | hyperandrogenism in women with polycystic ovary syndrome persists after menopause. |
PubMedID- 20378617 | Background: the present study was designed to evaluate whether the alteration of aquaporin-9 (aqp-9) expression in granulosa cells (gcs) of patients with polycystic ovary syndrome (pcos) was associated with the hyperandrogenism in follicular fluid (ff). |
PubMedID- 26327890 | The available research suggests that hyperandrogenism featuring women with polycystic ovary syndrome (pcos) during their reproductive life persists also after menopause. |
PubMedID- 25591557 | Identification of differentially expressed micrornas in the ovary of polycystic ovary syndrome with hyperandrogenism and insulin resistance. |
PubMedID- 26236094 | In healthy female rats, a model of polycystic ovary syndrome with ir and hyperandrogenism, is induced by h-dages. |
PubMedID- 22837189 | polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic pcos phenotypes and healthy controls, independent of obesity and insulin resistance. |
PubMedID- 25006485 | Although chronic hyperandrogenism, a typical feature of polycystic ovary syndrome, is often associated with disturbed reproductive performance, androgens have been shown to promote ovarian follicle growth in shorter exposures. |
PubMedID- 26491443 | Similarly both men and women could suffer from various forms of metabolic dysfunction and abnormalities due to androgen imbalance, including hypoandrogenism in aging men and hyperandrogenism in women with polycystic ovary syndrome (pcos) . |
PubMedID- 24895496 | Ovarian hyperandrogenism is a hallmark of polycystic ovary syndrome (pcos) and insulin resistance (ir) is a common finding in these women . |
PubMedID- 25246891 | Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (pcos) and women with non-classic congenital adrenal hyperplasia (ncah). |
PubMedID- 22086521 | Objectives: the pelvic floor muscles are sensitive to androgens, and due to hyperandrogenism, women with polycystic ovary syndrome can have increased mass in these muscles compared to controls. |
PubMedID- 22421986 | Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome. |
PubMedID- 22522778 | Aim: we aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (pcos). |
PubMedID- 26491440 | The role of androgens in females is not well established, but many lines of evidence indicate that hyperandrogenism in women with polycystic ovary syndrome (pcos) increases risk of developing nafld. |
PubMedID- 20036327 | Insulin and hyperandrogenism in women with polycystic ovary syndrome. |
PubMedID- 23155436 | hyperandrogenism is characteristic of women with polycystic ovary syndrome (pcos). |
PubMedID- 22651247 | The hyperandrogenism in women with polycystic ovary syndrome is frequently, but not consistently, associated with increased total and abdominal adiposity . |
PubMedID- 23450052 | Background: polycystic ovary syndrome (pcos) is associated with hyperandrogenism and insulin resistance. |
PubMedID- 21986157 | Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the southeastern region of turkey. |
PubMedID- 23812344 | Background: polycystic ovary syndrome (pcos) is associated with hyperandrogenism and an increased risk of type 2 diabetes and cardiovascular disease. |
PubMedID- 26295295 | Obesity, insulin resistance (ir), inflammation, and hyperandrogenism may lead to polycystic ovary syndrome (pcos) and hypertension. |
PubMedID- 20146169 | polycystic ovary syndrome (pcos) is associated with hyperandrogenism, insulin resistance (ir), and chronic inflammation. |
PubMedID- 21622477 | Single nucleotide polymorphisms (snps) in hsd11b1, the gene encoding 11beta-hsd1, have been associated with type 2 diabetes and hypertension in population-based cohort studies, and with hyperandrogenism in patients with the polycystic ovary syndrome (pcos). |
PubMedID- 24152688 | Context: statins have been shown to improve hyperandrogenism in women with polycystic ovary syndrome (pcos). |
Page: 1